Media Coverage

Cleveland Clinic's 16th annual Medical Innovation Summit, scheduled for Oct. 22-24 in downtown Cleveland, will center around the theme of "Disruption: Reimagining Healthcare."[CR-LF][CR-LF]The summit — organized by Cleveland Clinic Innovations, the system's development and commercialization arm — is anticipated to gather more than 100 speakers, as well as leaders from more than 500 organizations and 20 countries, according to a news release. It will be held at the Huntington Convention Center. According to the release, other featured speakers include Nigel Clarke, vice president of technology and solutions development for Quest Diagnostics.

Two conflicting trends are hitting the United States: a continuing shortage of qualified or willing candidates for truck driving jobs, and the increasing state-level legalization of medical or recreational marijuana. The two trends certainly don’t mix. David Couch, the Little Rock attorney who wrote the medical marijuana amendment voters approved in 2016, doesn’t want marijuana users driving big rigs any more than the most anti-pot politician does.A recent study by Quest Diagnostics, the national drug testing lab service, reported that overall drug use in the tested workforce is down in Arkansas. The national rate held steady at 4.2 percent of the workforce, while the state rate dropped from 6 percent in 2016 to 5 percent in 2017. The study measured individual drugs as well.

As we first reported last May, Holmes founded the start-up Theranos and boasted her technology could take a pin-prick worth of blood from the finger and perform hundreds of laboratory tests. It was, she claimed, "the most important thing humanity has ever built." At its zenith, Theranos was worth nearly $10 billion and Elizabeth Holmes became the youngest, self-made, female billionaire in the world. Today, she and her company's one-time president stand criminally charged by the U.S. government of perpetrating a "multi-million dollar scheme" to defraud investors, doctors and patients. Elizabeth Holmes built her company Theranos on this invention she named the Edison. A miniaturized blood analyzer that would disrupt the $60 billion lab testing industry dominated by giants LabCorp and Quest Diagnostics.

Although more than half of Americans misuse prescription drugs, the percentage that did so has held steady for four consecutive years, according to a new analysis. Meanwhile, though, there has also been a surge in the use of illicit drugs and medicines obtained without a prescription among patients being treated for substance use disorders.

The countless drops of sweat covering their drenched bodies are indicative of the hard work put in by the New York Giants throughout the hot and humid summer. Those same droplets were also analyzed and examined to help individual performance. The Giants used a new sweat test this year to make sure their players were properly hydrated and prepared for the rigors of summer. It should continue to help them throughout the season. It’s not a completely new idea, just a refined version of a sweat test. There are other teams using different variations of this new patch the Giants had analyzed by Quest Diagnostics as part of their Blueprint for Athletes program. This iteration is easier to implement and is believed to be more effective than the previous processes they have tried over the past few years. The hope is that its benefits can stretch throughout the year and provide even the slightest of competitive advantages.

Prescription data alone underestimated how many patients combined opioids and benzodiazepines, an analysis of Quest Diagnostics drug test data indicated. Among a selected sample of patients whose drug test indicated concurrent benzodiazepine and opioid use, 64% had at least one benzodiazepine or opioid that was not prescribed, according to Quest researcher Leland McClure, PhD, and colleagues in a poster presentation at the 2018 PAINWeek conference.

Genomic Vision, a company specializing in the development of diagnostic tests for the early detection of cancers and hereditary diseases, and applications for life sciences research, today announces the second payment from its collaboration with Quest Diagnostics on biomarker identification of currently undetected “2+0” SMA carriers following the Milestone program signed in 2018. A first Milestone (1a) was reached at the end of 2017, resulting in the design and validation of a new GMC covering with higher precision the complex SMA region. The goal of the second Milestone (1b) consisted in performing complementary experiments and analysis on existing samples in order to identify smaller biomarkers for SMN1 cis-duplication potentially leading to SMA diagnostic test.

Quest Diagnostics announced Tuesday it will acquire the US laboratory testing business of Oxford Immunotec Global for $170 million in cash. As part of the definitive agreement reached by the companies, the acquisition will include the T-Spot.TB tuberculosis testing service and the Accutix tick-borne disease testing service provided by Oxford Immunotec laboratories in Norwood, Massachusetts and in Memphis, Tennessee. Oxford Immunotec is headquartered in Abingdon, UK.

More than half of Americans tested by Quest Diagnostics in 2017 misused prescription drugs, a statistic that has remained relatively flat and suggests that medication adherence is more difficult as the opioid epidemic swells. The misuse rate — meaning tests reveal additional drugs (non-prescribed or illicit), different medications than prescribed, or no prescription or illicit drugs — was 52% in 2017 and 2016, and has remained relatively stagnant since 2013, according to Quest Diagnostics' analysis of 3.9 million clinical drug monitoring tests administered between 2011 and 2017.

Hooper Holmes, Inc. d/b/a Provant Health , the largest publicly traded, pure-play health and well-being provider in the U.S., today announced that it has entered into an asset purchase agreement with Summit Health, Inc., a subsidiary of Quest Diagnostics (“Quest”), the world’s leading provider of diagnostic testing, information, and services. Under the asset purchase agreement, Quest will acquire substantially all of Provant Health’s assets and will continue the Company’s service offerings as it has in the past. Throughout the transaction process, Provant Health will continue to serve its customers, remaining focused on meeting customer and partner obligations in the busy fourth quarter season.